Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial

Abstract

Background Long-term intraocular injections of vascular endothelial growth factor (VEGF)-neutralising proteins can preserve central vision in many patients with neovascular age-related macular degeneration. We tested the safety and tolerability of a single intravitreous injection of an AAV2 vector expressing the VEGF-neutralising protein sFLT01 in patients with advanced neovascular age-related macular degeneration. Methods This was a phase 1, open-label, dose-escalating study done at four outpatient retina clinics in the USA. Patients were assigned to each cohort in order of enrolment, with the first three patients being assigned to and completing the first cohort before filling positions in the following treatment groups. Patients aged 50 years or older with neovascular age-related macular degeneration and a baseline best-corrected visual acuity score of 20/100 or less in the study eye were enrolled in four dose-ranging cohorts (cohort 1, 2 × 10 8 vector genomes (vg); cohort 2, 2 × 10 9 vg; cohort 3, 6 × 10 9 vg; and cohort 4, 2 × 10 10 vg, n=3 per cohort) and one maximum tolerated dose cohort (cohort 5, 2 × 10 10 vg, n=7) and followed up for 52 weeks. The primary objective of the study was to assess the safety and tolerability of a single intravitreous injection of AAV2-sFLT01, through the measurement of eye-related adverse events. This trial is registered with ClinicalTrials.gov, number NCT01024998. Findings 19 patients with advanced neovascular age-related macular degener…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30979-0

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

10 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 29 references

Cited by

See all 229

Metadata

Authors
Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., Connelly, J., Wadsworth, S. C., Varona, R., Buggage, R., Scaria, A., & Campochiaro, P. A.
Affiliations
  • Ophthalmic Consultants of Boston (US)
  • Johns Hopkins University (US)
  • Retinal Consultants of Arizona (US)
  • University of Massachusetts Chan Medical School (US)
Corresponding author
Campochiaro, Peter A
Venue
The Lancet
Publisher
Elsevier BV
Published
2017-07
Volume
390
Issue
10089
Pages
50-61
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2615193664
Cited by
229
References
29
Citations by year
2026: 9 · 2025: 22 · 2024: 31 · 2023: 23 · 2022: 24 · 2021: 40 · 2020: 25 · 2019: 20 · 2018: 23 · 2017: 12
FWCI
21.34
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
neovascular age-related macular degeneration, AAV2 vector, anti-VEGF therapy, safety and tolerability, visual acuity, retinal pigment epithelium, choroidal neovascularization, intraocular inflammation, dose-limiting toxicity
MeSH terms
Dependovirus, Aged, Aged, 80 and over, Female, Genetic Vectors, Humans, Macular Degeneration, Male, Middle Aged, Recombinant Fusion Proteins, Visual Acuity, Genetic Therapy, Parvovirinae, Choroidal Neovascularization, Angiogenesis Inhibitors, Tomography, Optical Coherence, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. https://app.cochat.ai/papers/10.1016/s0140-6736(17)30979-0
The paper
Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., Connelly, J., Wadsworth, S. C., Varona, R., Buggage, R., Scaria, A., & Campochiaro, P. A. (2017). Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. The Lancet. https://doi.org/10.1016/s0140-6736(17)30979-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.